Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report

Abstract

We present an 88-year-old male with simultaneous T-cell prolymphocytic leukemia and stable smoldering myeloma with excellent initial response to three months of alemtuzumab. The patient relapsed at twelve months with severe cutaneous disease. Biopsy of a representative plaque demonstrated CD30 positivity in rare malignant lymphocytes. The patient demonstrated no response to reintroduction with a full course of alemtuzumab. He was therefore treated with brentuximab vedotin, resulting in partial remission of skin involvement that persisted for three months.

Keywords

• T-prolymphocytic leukemia
• brentuximab vedotin
• alemtuzumab